Franklin Genomic Advancements ETF (HELX)

Assets	$11.25M
Expense Ratio	0.50%
PE Ratio	20.84
Shares Out	350,000
Dividend (ttm)	n/a
Dividend Yield	n/a
Ex-Dividend Date	n/a
Payout Ratio	n/a
1-Year Return	+20.95%

Volume	6,404
Open	32.28
Previous Close	32.37
Day's Range	31.86 - 32.28
52-Week Low	25.26
52-Week High	33.98
Beta	1.07
Holdings	64
Inception Date	Feb 25, 2020

About HELX

Fund Home Page

The Franklin Genomic Advancements ETF (HELX) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed portfolio of global equity securities of companies relevant to genomic discovery. HELX was launched on Feb 25, 2020 and is issued by Franklin Templeton.

• Asset Class: Equity
• Category: Health
• Region: Global
• Stock Exchange: BATS
• Ticker Symbol: HELX
• ETF Provider: Franklin Templeton

Top 10 Holdings

46.44% of assets

Name	Symbol	Weight
Medpace Holdings, Inc.	MEDP	5.91%
Vertex Pharmaceuticals Incorporated	VRTX	5.79%
Danaher Corporation	DHR	5.27%
Regeneron Pharmaceuticals, Inc.	REGN	5.00%
Eli Lilly and Company	LLY	4.97%
Thermo Fisher Scientific Inc.	TMO	4.96%
Krystal Biotech, Inc.	KRYS	4.25%
Natera, Inc.	NTRA	3.80%
Samsung Biologics Co.,Ltd.	207940	3.80%
AstraZeneca PLC	AZN	2.68%